Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT06682793

Recruiting now Disease control Sponsor: A2 Biotherapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to find a safe dose, then to see if it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A2B395 (a type of CAR T-cell therapy made from donor cells)
What this could lead to: If successful, this could provide a new treatment option for several hard-to-treat cancers that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 240 participants, so the treatment may not work or could cause serious side effects like cytokine release syndrome or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colon carcinoma colonic neoplasm colorectal adenocarcinoma colorectal cancer colorectal carcinoma colorectal neoplasm head and neck squamous cell carcinoma kidney cancer lung cancer lung neoplasm neoplasm non-small cell lung carcinoma rectal cancer rectal neoplasm renal cell carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER COLON CANCER COLORECTAL ADENOCARCINOMA COLORECTAL CANCER CRC HEAD AND NECK SQUAMOUS CELL CANCER HNSCC KIDNEY CANCER LUNG CANCER NON-SMALL-CELL LUNG NSCLC (NON-SMALL CELL LUNG CANCER) RCC RECTAL CANCER RENAL CELL CARCINOMA SOLID TUMOR, ADULT TNBC TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Banner MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Fred Hutch Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33606, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
UCLA Medical Center
RECRUITING

Los Angeles, California, 90404, United States
UCSD Moores Cancer Center
RECRUITING

La Jolla, California, 92093, United States
Washington University
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.